.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have identified that ATM deficiency pancreatic cancer significantly alters the tumor microenvironment (TME) through specific genetic pathways. This genotype-specific reprogramming enhances cancer aggressiveness by influencing bidirectional tumor-stroma interactions. Specifically, the loss of ATM serine/threonine kinase drives the differentiation of cancer-associated fibroblasts (CAFs) into a myofibroblastic phenotype (myCAF). This process occurs independently of the p53 status, highlighting a unique role for ATM in structural tumor dynamics.
The study demonstrates that ATM loss increases reactive oxygen species and enhances contractility signaling within the epithelium. Consequently, this leads to an elevated secretion of TGF-β1. This signaling molecule acts as a primary messenger that transforms the surrounding niche into a cancer-promoting environment. Moreover, the resulting myCAFs contribute directly to chemoresistance, making traditional treatments less effective for patients with this specific genetic profile.
Pharmacological inhibition of the TGF-β pathway shows significant clinical promise. In experimental models, blocking this signal reversed myCAF differentiation and sensitized tumors to chemotherapy. Therefore, dual targeting of both the intrinsic epithelial defects and the extrinsic stromal vulnerabilities represents a potent precision oncology strategy. These findings emphasize the importance of identifying the ATM status in patients to tailor more effective therapeutic interventions.
ATM loss increases TGF-β1 secretion, which reprograms fibroblasts into myofibroblasts, creating a niche that supports tumor growth and resists chemotherapy.
Yes, research indicates that TGF-β inhibition can reverse aggressive stromal changes and improve the efficacy of chemotherapy in ATM-deficient models.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
New research shows ATM deficiency in pancreatic cancer triggers TGF-β signaling to create an aggressive niche, offering promising precision oncology targets...
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
